

Clinical Policy: Trofinetide (Daybue, Daybue Stix)

Reference Number: LA.PHAR.600

Effective Date: 10.25.23

Last Review Date: ~~05.12.25~~01.27.26

Line of Business: Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Trofinetide (DaybueTM, Daybue[®] Stix) is an insulin-like growth factor 1 (IGF-1) analog.

FDA Approved Indication(s)

Daybue ~~is~~and Daybue Stix are indicated for the treatment of Rett syndrome (RTT) in adults and pediatric patients 2 years of age and older.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections[®] that Daybue ~~is~~and Daybue Stix are medically necessary when the following criteria are met:

I. Initial Approval Criteria**A. Rett Syndrome** (must meet all):

1. Diagnosis of RTT with both of the following (a and b):
 - a. Classic/typical RTT (*see Appendix D*);
 - b. *MECP2* gene mutation confirmed by genetic testing;
2. Prescribed by or in consultation with a pediatric neurologist, geneticist, or developmental pediatrician;
3. Age \geq 2 years;
4. Weight \geq 9 kg;
5. Member has had no seizures or has a stable pattern of seizures (e.g., no changes in seizure frequency, antiepileptic drugs, or behavioral treatments);
6. Documentation of one of the following baseline assessment scores (a or b):
 - a. Rett Syndrome Behavior Questionnaire (RSBQ) (*see Appendix E*);
 - b. Clinical Global Impression-Severity (CGI-S) of \geq 4 (*see Appendix F*);
7. At the time of request, member does not have either of the following (a and b):
 - a. Long QT syndrome or baseline QTcF interval $>$ 450 msec;
 - b. Current treatment with insulin;
8. Dose does not exceed anyone of the following (a, ~~b~~, ~~c~~, ~~d~~, or ~~eb~~):
 - a. For Daybue oral solution, one of the following (i-v):
 - ~~a.i.~~ Weight 9 kg to $<$ 12 kg: 10,000 mg (50 mL) per day;
 - ~~b.ii.~~ Weight 12 kg to $<$ 20 kg: 12,000 mg (60 mL) per day;

Formatted

Formatted: Bullets and Numbering

Formatted: Tab stops: 5.24", Left + Not at 4.89"

CLINICAL POLICY
Trofinetide

- ~~e.iii.~~ Weight 20 kg to < 35 kg: 16,000 mg (80 mL) per day;
- ~~d.iv.~~ Weight 35 kg to < 50 kg: 20,000 mg (100 mL) per day;
- ~~e.v.~~ Weight ≥ 50 kg: 24,000 mg (120 mL) per day;
- b. For Daybue Stix packets, one of the following (i-v):**
 - i. Weight 9 kg to < 12 kg, and both of the following per day (1 and 2):**
 - 1) 10,000 mg;
 - 2) Two 5,000 mg packets;
 - ii. Weight 12 kg to < 20 kg, and both of the following per day (1 and 2):**
 - 1) 12,000 mg;
 - 2) Two 6,000 mg packets;
 - iii. Weight 20 kg to < 35 kg, and both of the following per day (1 and 2):**
 - 1) 16,000 mg;
 - 2) Two 8,000 mg packets;
 - iv. Weight 35 kg to < 50 kg, and both of the following per day (1 and 2):**
 - 1) 20,000 mg;
 - 2) Four 5,000 mg packets;
 - v. Weight ≥ 50 kg, and both of the following per day (1 and 2):**
 - 1) 24,000 mg;
 - 2) Four 6,000 mg packets.

Approval duration: ~~6~~12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy ~~for the relevant line of business: LA.PMN.53 for Medicaid.~~

II. Continued Therapy

A. Rett Syndrome (must meet all):

- ~~a.~~ **1.** Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
- ~~2.~~ **2.** Member is responding positively to therapy; as evidenced by, including but not limited to, improvement in any of the following parameters (a, b, or c):
 - a. ≥ 3-point reduction in overall RSBQ total score from baseline;
 - b. If the member has received Daybue or Daybue Stix for 6 months or less, they currently must have a CGI-I score between 1-4;
 - c. If the member has received Daybue or Daybue Stix for more than 6 months, they currently must have a CGI-I score between 1-3;
- ~~3.~~ **3.** If request is for a dose increase, new does not exceed anyone of the following (a-~~or~~ b, ~~e, d, or e~~):
 - a. For Daybue oral solution, one of the following (i-v):**

Formatted: Normal, No bullets or numbering

Formatted: Font color: Black

Formatted: Normal, Indent: Left: 0.5", No bullets or numbering

Formatted: Normal, Indent: Left: 0.5", No bullets or numbering

Formatted: Indent: Left: 1", No bullets or numbering

CLINICAL POLICY
Trofinetide

- ~~a.i.~~ Weight 9 kg to < 12 kg: 10,000 mg (50 mL) per day;
- ~~b.ii.~~ Weight 12 kg to < 20 kg: 12,000 mg (60 mL) per day;
- ~~e.iii.~~ Weight 20 kg to < 35 kg: 16,000 mg (80 mL) per day;
- ~~d.iv.~~ Weight 35 kg to < 50 kg: 20,000 mg (100 mL) per day;
- ~~e.v.~~ Weight ≥ 50 kg: 24,000 mg (120 mL) per day;
- b. For Daybue Stix packets, one of the following (i-v):**
 - i. Weight 9 kg to < 12 kg, and both of the following per day (1 and 2):
 - 1) 10,000 mg;
 - 2) Two 5,000 mg packets;
 - ii. Weight 12 kg to < 20 kg, and both of the following per day (1 and 2):
 - 1) 12,000 mg;
 - 2) Two 6,000 mg packets;
 - iii. Weight 20 kg to < 35 kg, and both of the following per day (1 and 2):
 - 1) 16,000 mg;
 - 2) Two 8,000 mg packets;
 - iv. Weight 35 kg to < 50 kg, and both of the following per day (1 and 2):
 - 1) 20,000 mg;
 - 2) Four 5,000 mg packets;
 - v. Weight ≥ 50 kg, and both of the following per day (1 and 2):
 - 1) 24,000 mg;
 - 2) Four 6,000 mg packets.

Approval duration: ~~6~~12 months

A. ~~B.~~ Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy ~~for the relevant line of business: LA.PMN.53 for Medicaid.~~

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy ~~ies~~ LA.PMN.53 ~~for Medicaid, or evidence of coverage documents.~~

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CGI-I: Clinical Global Impression-Improvement

CGI-S: Clinical Global Impression-Severity

FDA: Food and Drug Administration

IGF-1: insulin-like growth factor 1

RSBQ: Rett Syndrome Behavior Questionnaire

RTT: Rett syndrome

Formatted: Tab stops: 5.24", Left + Not at 4.89"

Formatted

Formatted: Bullets and Numbering

Formatted: Indent: Left: 1", No bullets or numbering

Formatted: Normal, Indent: Left: 0.5", First line: 0.5", No bullets or numbering

Formatted: Indent: Left: 1.25", No bullets or numbering

Formatted: Indent: Left: 1.5", No bullets or numbering

Formatted: Indent: Left: 1.25", No bullets or numbering

Formatted: Indent: Left: 1.5", No bullets or numbering

Formatted: Indent: Left: 1.25", No bullets or numbering

Formatted: Indent: Left: 1.5", No bullets or numbering

Formatted: Indent: Left: 1.25", No bullets or numbering

Formatted: Indent: Left: 1.5", No bullets or numbering

Appendix B: Therapeutic Alternatives
 Not applicable

Appendix C: Contraindications/Boxed Warnings
 None reported

Appendix D: General Information

- RTT is a rare neurodevelopment disorder that occurs almost exclusively in females; however, there have been cases seen in males.
- Mutations on the *MECP2* gene occur in 90-95% of RTT cases.
 - The *MECP2* gene is imperative for the normal functioning of nerve cells.
- According to the International Rett Syndrome Foundation, classical/typical RTT is defined by these criteria:
 - Main criteria
 - Partial or complete loss of acquired purposeful hand skills
 - Partial or complete loss of acquired spoken language
 - Gait abnormalities: impaired or absence of ability to walk
 - Hand wringing/squeezing/clapping, mouthing, and/or washing/rubbing that seems habitual or uncontrollable (stereotypical of RTT)
 - Exclusion criteria
 - Brain injury secondary to trauma, neurometabolic disease, or severe infection that causes neurological problems
 - Grossly abnormal psychomotor development in the first 6 months of life
 - Supportive criteria
 - Breathing disturbances when awake, bruxism when awake, abnormal muscle tone, impaired sleep pattern, peripheral vasomotor disturbances, scoliosis/kyphosis, growth retardation, small cold hands and feet, inappropriate laughing/screaming spells, diminished response to pain, intense eye communication-use of eye pointing
 - Required criteria for classical RTT
 - A period of regression followed by recovery or stabilization
 - All main criteria and all exclusion criteria
 - Supportive criteria are not required, though often present in typical RTT
- Individuals with RTT may also suffer from seizures, autism, cardiovascular dysfunction, and gastrointestinal issues, often requiring a gastrostomy tube.

Appendix E: Rett Syndrome Behavior Questionnaire (RSBQ)

The RSBQ is used to assess characteristics of RTT. It consists of 45 questions across eight categories, each question with three answers at values of 0, 1, and 2; 0 corresponds to “never”, 1 to “sometimes”, and 2 to “always”.

RSBQ Category
General mood
Breathing problems
Hand behaviors
Repetitive face movements
Body rocking and expressionless face

Formatted Table

CLINICAL POLICY
Trofinetide



RSBQ Category
Night-time behaviors
Fear/anxiety
Walking/standing
Total (max score = 90)

Formatted Table

Appendix F: Clinical Global Impression Score

Score rated on a 7-point scale used to determine if illness was improved or worsened.

CGI-S	CGI-I	Score
Normal	Very much improvement	1
Borderline ill	Much improved	2
Mildly ill	Minimally improved	3
Moderately ill	No change	4
Markedly ill	Minimally worse	5
Severely ill	Much worse	6
Extremely ill	Very much worse	7

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose																		
RTT	<p>Dose can be given orally or via gastrostomy tube or gastrojejunal tube</p> <ul style="list-style-type: none"> Weight 9 kg to < 12 kg: 5,000 mg (25 mL) twice daily Weight 12 kg to < 20 kg: 6,000 mg (30 mL) twice daily Weight 20 kg to < 35 kg: 8,000 mg (40 mL) twice daily Weight 35 kg to < 50 kg: 10,000 mg (50 mL) twice daily Weight ≥ 50 kg: 12,000 mg (60 mL) twice daily <p><u>Recommended Daybue oral solution volume and Daybue Stix packets for oral solution needed to prepare each dose:</u></p> <table border="1"> <thead> <tr> <th>Dose</th> <th>Daybue oral solution volume</th> <th>Daybue Stix packets</th> </tr> </thead> <tbody> <tr> <td><u>5,000 mg</u></td> <td><u>25 mL</u></td> <td><u>one 5,000 mg packet</u></td> </tr> <tr> <td><u>6,000 mg</u></td> <td><u>30 mL</u></td> <td><u>one 6,000 mg packet</u></td> </tr> <tr> <td><u>8,000 mg</u></td> <td><u>40 mL</u></td> <td><u>one 8,000 mg packet</u></td> </tr> <tr> <td><u>10,000 mg</u></td> <td><u>50 mL</u></td> <td><u>two 5,000 mg packets</u></td> </tr> <tr> <td><u>12,000 mg</u></td> <td><u>60 mL</u></td> <td><u>two 6,000 mg packets</u></td> </tr> </tbody> </table>	Dose	Daybue oral solution volume	Daybue Stix packets	<u>5,000 mg</u>	<u>25 mL</u>	<u>one 5,000 mg packet</u>	<u>6,000 mg</u>	<u>30 mL</u>	<u>one 6,000 mg packet</u>	<u>8,000 mg</u>	<u>40 mL</u>	<u>one 8,000 mg packet</u>	<u>10,000 mg</u>	<u>50 mL</u>	<u>two 5,000 mg packets</u>	<u>12,000 mg</u>	<u>60 mL</u>	<u>two 6,000 mg packets</u>	24,000 mg/day
Dose	Daybue oral solution volume	Daybue Stix packets																		
<u>5,000 mg</u>	<u>25 mL</u>	<u>one 5,000 mg packet</u>																		
<u>6,000 mg</u>	<u>30 mL</u>	<u>one 6,000 mg packet</u>																		
<u>8,000 mg</u>	<u>40 mL</u>	<u>one 8,000 mg packet</u>																		
<u>10,000 mg</u>	<u>50 mL</u>	<u>two 5,000 mg packets</u>																		
<u>12,000 mg</u>	<u>60 mL</u>	<u>two 6,000 mg packets</u>																		

Formatted Table

Formatted: Normal, No bullets or numbering

VI. Product Availability

~~Oral solution: 200 mg/mL~~

CLINICAL POLICY
Trofinetide



Drug Name	Availability
Trofinetide (Daybue)	Oral solution: 200 mg/mL
Trofinetide (Daybue Stix)	Packets containing powder for oral solution: 5,000 mg, 6,000 mg, 8,000 mg

Formatted: Font color: Auto

Formatted: List Paragraph, Indent: Left: 0.25"

VII. References

1. Daybue and Daybue Stix Prescribing Information. San Diego, CA: Acadia Pharmaceuticals Inc.; ~~September 2024-December 2025~~. Available at: ~~https://daybue-prescribing-information.com/daybue-pi.pdf~~. Accessed ~~January 14~~December 29, 2025.
2. Neul JL, Percy AK, Benke TA, et al. Design and outcome measures of Lavender, a phase 3 study of trofinetide for Rett Syndrome. Contemporary Clinical Trials. 2022;114:106704. doi:10.1016/j.cct.2022.106704.
3. Neul JL, Glaze DG, Percy AK, et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the Clinical Global Impression scale. J Child Neurol. 2015;30(13):1743-1748. doi:10.1177/0883073815579707.
4. Cianfaglione R, Clarke A, Kerr M, et al. A national survey of Rett syndrome: behavioural characteristics. J Neurodevelop Disord. 2015;7(1):11.
5. Glaze DG, Neul JL, Kaufmann WE, et al. Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome. Neurology. 2019;92(16):e1912-e1925. doi:10.1212/wnl.00000000000007316.
6. Fu C, Armstrong D, Marsh E, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. Sep 2020;4(1):e000717.
7. Rett syndrome diagnosis. Rettsyndrome.org. Available at: https://www.rettsyndrome.org/about-rett-syndrome/rett-syndrome-diagnosis/. Accessed September 29, 2022.
8. NIH.gov. Rett syndrome | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program. Published 2014. Available at: https://rarediseases.info.nih.gov/diseases/5696/rett-syndrome. Accessed September 29, 2022.

Formatted: Font color: Auto

Formatted: Font color: Auto

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created.	05.01.23	09.25.23
Annual review: no significant changes; references reviewed and updated.	05.08.24	07.29.24
Annual review: no significant changes; references reviewed and updated	05.12.25	<u>N/A, no material revisions</u>
<u>Added new Daybue Stix formulation; revised approval durations to 12 months.</u>	<u>01.27.26</u>	

Formatted: Font: 11 pt

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

CLINICAL POLICY

Trofinetide



approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2026 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare

CLINICAL POLICY
Trofinetide



Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.